We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Carolyn
Bodycote
carolyn.bodycote@nhs.net
Carolyn
Bodycote
uhl-tr.dominostudy@nhs.net
Lauren
Senior
uhl-tr.dominostudy@nhs.net
Laura
Kusinski
laura.kusinski@leicester.ac.uk
Claire
Meek
cm881@leicester.ac.uk
Laura
Kusinski
uhl-tr.dominostudy@nhs.net
Sahar
Khodabakhsh
uhl-tr.dominostudy@nhs.net
Lauren
Senior
lauren.senior5@nhs.net
Other maternal disorders predominantly related to pregnancy
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Despite recent improvements in diabetes technology,pregnancy remains a very challenging time for women
with type 1 diabetes (T1D),and a good outcome is not guaranteed. Many affected women have babies with
complications,such as large birthweight or low blood glucose levels (neonatal hypoglycaemia) who may need admitted to the neonatal intensive care unit. Although improving maternal glucose levels reduces complication rates,we are still unable to predict exactly which pregnancies are at highest risk of complications. This means that all women are treated according to the same care pathway,instead of having the opportunity for more personalised care based on an individual risk prediction.
Our recent research has suggested that patterns of C-peptide,a blood marker which indicates the function of pancreatic beta cells which normally produce insulin,can identify pregnancies at high risk of complications. The aim of our study is to identify if the C-peptide biomarker could be used to predict and prevent complications in T1D pregnancy. Using the C-peptide biomarker to find the highest risk babies,we will assess if extra monitoring or enhanced care pathways can prevent complications such as neonatal hypoglycaemia. Additionally,pregnancy in women with early-onset type 2 diabetes (EOT2D) (diagnosis before age 40 years) is becoming more common. These pregnancies can have huge risks for mothers and their children. Around 1 in 10 women who have high blood glucose levels when they become pregnant have a stillbirth or newborn death. Babies who do survive are more likely to have a high birthweight,birth injuries,and neonatal hypoglycaemia (very low levels of blood sugars).
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
• Diagnosis of diabetes,which is not type 1 diabetes or EOT2D (example MODY).
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Laura
Kusinski
laura.kusinski@leicester.ac.uk
Carolyn
Bodycote
carolyn.bodycote@nhs.net
Claire
Meek
cm881@leicester.ac.uk
Laura
Kusinski
uhl-tr.dominostudy@nhs.net
Sahar
Khodabakhsh
uhl-tr.dominostudy@nhs.net
Carolyn
Bodycote
uhl-tr.dominostudy@nhs.net
Lauren
Senior
uhl-tr.dominostudy@nhs.net
Lauren
Senior
lauren.senior5@nhs.net
The study is sponsored by University of Leicester and funded by THE BRITISH DIABETIC ASSOCIATION (DIABETES UK) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 64155
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
